Open access
Oct 2026
Risk factors for shorter recurrence-free survival in patients with resected biliary tract cancer treated with adjuvant S-1 chemotherapy.
BACKGROUND Adjuvant S-1 chemotherapy (ASC) has become the standard postoperative treatment for biliary tract cancer (BTC) in Japan following publication of the results of the ASCOT study, a recent nationwide randomized controlled study. However, recurrence remains common, and risk factors specific to patients treated w...
T. Taira, Mitsuhito Sasaki, G. Igarashi et al.
· International Journal of Cli... · 0 citations